Found 5 matching trials
SAR3419 Administered Weekly in Patients With Relapsed/Refractory CD19-positive B-cell Non-Hodgkin's Lymphoma
PHASE1The primary objective is to determine the maximum tolerated dose (MTD) of S...
Location
Sanofi-Aventis Investigational Site Number 250004
SAR3419 as Single Agent in Relapsed-Refractory Diffuse Large B-Cell Lymphoma (DLBCL) Patients
PHASE2Primary Objective:
Participants achieving an Objective Response Rate
Seco...
Location
Investigational Site Number 840001
Multi-dose-escalation Safety and Pharmacokinetic Study of SAR3419 as Single Agent in Relapsed/Refractory B-cell Non Hodgkin's Lymphoma
PHASE1The primary objective is to determine the maximum tolerated dose of SAR3419...
Location
Sanofi-Aventis Administrative Office
SAR3419 in Acute Lymphoblastic Leukemia
PHASE2Primary Objective:
Participants achieving an Objective Response Rate
Seco...
Location
Investigational Site Number 840006
Combination of SAR3419 and Rituximab in Relapsed/Refractory Diffuse Large B-Cell Lymphoma
PHASE2Primary Objective:
Participants Achieving an Objective Response Rate (Ches...
Location
Investigational Site Number 040002